IL-12 Melonoma
I suppose topline results for the P2 Melonoma stucy could come anytime. Perhaps the fact no data has yet come out, or perhaps rumors behind the scenes of failure to meet primary endpoints is driving the stock down. JRP was real optimistic about our technicals not that long ago and at time I generally thought he was right. So perhaps something bad is going on and the shoe has not yet dropped. It could be we are just getting battered like many other bios, but the silence from company is deafening.